Megumi Hamaguchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Megumi Hamaguchi has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
Takeshi Isobe
Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine Shimane University Faculty of Medicine Izumo Shimane Japan
8 shared publications- Yukari Tsubata
Department of Respiratory Medicine Gifu University Graduate School of Medicine Gifu Japan
7 shared publications Yoshihiro Amano
Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine Shimane University Faculty of Medicine Izumo Shimane Japan
6 shared publications- Takamasa Hotta
Division of Medical Oncology and Respiratory Medicine, Department of Internal Medicine, Shimane University Faculty of Medicine, Izumo, Japan
5 shared publications Mika Nakao
Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine Shimane University Faculty of Medicine Izumo Shimane Japan
4 shared publications- Misato Kobayashi
Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine Shimane University Faculty of Medicine Izumo Japan
4 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Wiley in Respirology Case Reports
- Vol. 14 (11)
Persistent Coronavirus Disease 2019 ( COVID ‐19) in Patients With Malignant Lymphoma Treated With Anti‐ CD20 Antibodies Who Responded to Ensitrelvir: A Report of Three Cases
Patients with malignant lymphoma receiving anti‐CD20 antibody therapy are at high risk of persistent coronavirus disease 2019 (COVID‐19), with no established standard treatment. We report three cases of persistent COVID‐19 in patients with follicular lymphoma who responded clinically after switching to ensitrelvir following the failure of remdesivir‐based treatment. Each patient had multiple relapses and an inadequate response to remdesivir but achieved symptom resolution with ensitrelvir. These cases suggest that switching to an antiviral with a different mechanism of action may be an effective therapeutic strategy for immunocompromised patients when initial antiviral therapies fail.
- 2 November 2026
- Published by Wiley in Respirology Case Reports
- Vol. 14 (11)
Open AccessPersistent Coronavirus Disease 2019 ( COVID ‐19) in Patients With Malignant Lymphoma Treated With Anti‐ CD20 Antibodies Who Responded to Ensitrelvir: A Report of Three Cases
Patients with malignant lymphoma receiving anti‐CD20 antibody therapy are at high risk of persistent coronavirus disease 2019 (COVID‐19), with no established standard treatment. We report three cases of persistent COVID‐19 in patients with follicular lymphoma who responded clinically after switching to ensitrelvir following the failure of remdesivir‐based treatment. Each patient had multiple relapses and an inadequate response to remdesivir but achieved symptom resolution with ensitrelvir. These cases suggest that switching to an antiviral with a different mechanism of action may be an effective therapeutic strategy for immunocompromised patients when initial antiviral therapies fail.
- Open Access
- 1 April 2026
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 21, 1-11
A Predicted FEV1/FVC Model Based on a Simple Respiratory Questionnaire for Early Diagnosis of COPD in Shimane Cohort, Japan
Purpose: Early detection of chronic obstructive pulmonary disease (COPD) remains challenging in primary care settings where spirometry is not always available. We aimed to develop a simple questionnaire-based approach to estimate the forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ratio for COPD screening. Patients and Methods: This was a single-center retrospective observational study based on the Shimane cohort. From 2008 to 2014, respiratory questionnaires and spirometry were performed during health check-ups of individuals aged ≥ 40 years. Among 2230 participants who underwent spirometry, 727 current or former smokers without a history of bronchial asthma were included for model development. Multiple regression analysis was used to identify questionnaire items associated with FEV1/FVC and to construct a simplified estimation model. Results: Four variables—age, smoking intensity, exertional dyspnea, and paroxysmal dyspnea—were independently associated with FEV1/FVC and were incorporated into the model. The model demonstrated modest explanatory power (R2 = 0.136), with no significant lack-of-fit (F = 1.152). Based on these variables, a simple four-item model enabled estimation of FEV1/FVC and identification of individuals at risk for airflow limitation. Conclusion: We developed a simple questionnaire-based model to estimate FEV1/FVC using four easily obtainable variables. Although the model is exploratory and requires external validation, it may serve as a practical screening tool to identify individuals at risk for COPD in settings where spirometry is not readily available. Plain Language Summary: Chronic obstructive pulmonary disease (COPD) is an important respiratory disease, but the need for spirometry for diagnosis makes early diagnosis difficult in primary care settings. We analyzed data from 727 smokers, selected from 13,280 patients aged 40 years or older, who underwent a respiratory interview and spirometry during an annual check-up. We found statistically significant differences in four parameters: age, smoking index, exertional breathlessness, and paroxysmal breathlessness in COPD patients compared with non-COPD patients. Therefore, we used these parameters to create a four-item-only predictive model for COPD screening. This model can be used to identify patients with possible COPD without spirometry for early diagnosis and appropriate COPD management.
- 1 April 2026
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 21, 1-11
Open AccessA Predicted FEV1/FVC Model Based on a Simple Respiratory Questionnaire for Early Diagnosis of COPD in Shimane Cohort, Japan
Purpose: Early detection of chronic obstructive pulmonary disease (COPD) remains challenging in primary care settings where spirometry is not always available. We aimed to develop a simple questionnaire-based approach to estimate the forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ratio for COPD screening. Patients and Methods: This was a single-center retrospective observational study based on the Shimane cohort. From 2008 to 2014, respiratory questionnaires and spirometry were performed during health check-ups of individuals aged ≥ 40 years. Among 2230 participants who underwent spirometry, 727 current or former smokers without a history of bronchial asthma were included for model development. Multiple regression analysis was used to identify questionnaire items associated with FEV1/FVC and to construct a simplified estimation model. Results: Four variables—age, smoking intensity, exertional dyspnea, and paroxysmal dyspnea—were independently associated with FEV1/FVC and were incorporated into the model. The model demonstrated modest explanatory power (R2 = 0.136), with no significant lack-of-fit (F = 1.152). Based on these variables, a simple four-item model enabled estimation of FEV1/FVC and identification of individuals at risk for airflow limitation. Conclusion: We developed a simple questionnaire-based model to estimate FEV1/FVC using four easily obtainable variables. Although the model is exploratory and requires external validation, it may serve as a practical screening tool to identify individuals at risk for COPD in settings where spirometry is not readily available. Plain Language Summary: Chronic obstructive pulmonary disease (COPD) is an important respiratory disease, but the need for spirometry for diagnosis makes early diagnosis difficult in primary care settings. We analyzed data from 727 smokers, selected from 13,280 patients aged 40 years or older, who underwent a respiratory interview and spirometry during an annual check-up. We found statistically significant differences in four parameters: age, smoking index, exertional breathlessness, and paroxysmal breathlessness in COPD patients compared with non-COPD patients. Therefore, we used these parameters to create a four-item-only predictive model for COPD screening. This model can be used to identify patients with possible COPD without spirometry for early diagnosis and appropriate COPD management.
- Open Access
- 17 March 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (3) , 365-372
Prognostic prediction for newly diagnosed patients with idiopathic interstitial pneumonia: JIPS Registry (NEJ030)
- 17 March 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (3) , 365-372
Open AccessPrognostic prediction for newly diagnosed patients with idiopathic interstitial pneumonia: JIPS Registry (NEJ030)
- Open Access
- 1 February 2024
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 63 (3) , 443-446
Lipoid Pneumonia Caused by Esophageal Achalasia
A 59-year-old man presented with esophageal achalasia complicated by lipoid pneumonia. Dysphagia and diffuse ground-glass shadows on computed tomography led to the diagnosis of esophageal achalasia. An analysis of bronchoalveolar lavage (BAL) revealed yellow BAL fluid, with two distinct layers. Oil droplets were observed in the upper layer. Macrophages that phagocytosed lipids were also observed. He was diagnosed with lipoid pneumonia secondary to esophageal achalasia. His lipoid pneumonia improved after peroral endoscopic myotomy because of the reduction in aspiration risk.
- 1 February 2024
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 63 (3) , 443-446
Open AccessLipoid Pneumonia Caused by Esophageal Achalasia
A 59-year-old man presented with esophageal achalasia complicated by lipoid pneumonia. Dysphagia and diffuse ground-glass shadows on computed tomography led to the diagnosis of esophageal achalasia. An analysis of bronchoalveolar lavage (BAL) revealed yellow BAL fluid, with two distinct layers. Oil droplets were observed in the upper layer. Macrophages that phagocytosed lipids were also observed. He was diagnosed with lipoid pneumonia secondary to esophageal achalasia. His lipoid pneumonia improved after peroral endoscopic myotomy because of the reduction in aspiration risk.
- Open Access
- 1 May 2023
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 16, 2125-2132
A Retrospective Study of Pneumococcal Pneumonia in Hospitalized Patients Aged ≥65 Years in Izumo, Japan: 2010 to 2014
In Japan, both a 23-valent pneumococcal polysaccharide vaccine (PPSV23) and a 13-valent pneumococcal conjugate vaccine (PCV13) are available. Although randomized controlled trials have examined the effects of pneumococcal vaccines, few epidemiological studies have investigated the onset of pneumococcal pneumonia in general practice. In Izumo, Shimane Prefecture, Japan, a public subsidy for PPSV23 inoculation began in November 2012. The subjects were pneumonia patients aged 65 and over who were admitted to a hospital in Izumo. This retrospective study analyzed the following data extracted from medical records: pneumococcal pneumonia prevalence, pneumonia severity, mortality rate, PPSV23 vaccination rate, and length of hospital stay. The 2 years before the start of the public subsidy were defined as the early phase, and the 2 years after the subsidy initiation were defined as the late phase. We compared the two phases in terms of PPSV23 vaccination rate, prevalence and severity of pneumococcal pneumonia, and mortality rate. We investigated data from a total of 1188 and 1086 patients in the early and late phases, respectively. The prevalence of pneumococcal pneumonia was 21.0% and 21.3% in the early and late phases, respectively. The mortality rate from pneumococcal pneumonia was 10.4% and 5.4% in the early and late phases, respectively (p = 0.080), indicating a 50% reduction. The PPSV23 vaccination rate (p < 0.001) and the comorbidity rates of chronic respiratory disease (p = 0.022) and chronic renal disease (p < 0.001) were significantly different between the early and late phases. This study showed that the rate of in-hospital deaths due to pneumococcal pneumonia was halved after the PPSV23 vaccine was subsidized. The causal relationship between the pneumococcal vaccination rate and the mortality rate of pneumococcal disease was unclear. Further investigation is deemed necessary.
- 1 May 2023
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 16, 2125-2132
Open AccessA Retrospective Study of Pneumococcal Pneumonia in Hospitalized Patients Aged ≥65 Years in Izumo, Japan: 2010 to 2014
In Japan, both a 23-valent pneumococcal polysaccharide vaccine (PPSV23) and a 13-valent pneumococcal conjugate vaccine (PCV13) are available. Although randomized controlled trials have examined the effects of pneumococcal vaccines, few epidemiological studies have investigated the onset of pneumococcal pneumonia in general practice. In Izumo, Shimane Prefecture, Japan, a public subsidy for PPSV23 inoculation began in November 2012. The subjects were pneumonia patients aged 65 and over who were admitted to a hospital in Izumo. This retrospective study analyzed the following data extracted from medical records: pneumococcal pneumonia prevalence, pneumonia severity, mortality rate, PPSV23 vaccination rate, and length of hospital stay. The 2 years before the start of the public subsidy were defined as the early phase, and the 2 years after the subsidy initiation were defined as the late phase. We compared the two phases in terms of PPSV23 vaccination rate, prevalence and severity of pneumococcal pneumonia, and mortality rate. We investigated data from a total of 1188 and 1086 patients in the early and late phases, respectively. The prevalence of pneumococcal pneumonia was 21.0% and 21.3% in the early and late phases, respectively. The mortality rate from pneumococcal pneumonia was 10.4% and 5.4% in the early and late phases, respectively (p = 0.080), indicating a 50% reduction. The PPSV23 vaccination rate (p < 0.001) and the comorbidity rates of chronic respiratory disease (p = 0.022) and chronic renal disease (p < 0.001) were significantly different between the early and late phases. This study showed that the rate of in-hospital deaths due to pneumococcal pneumonia was halved after the PPSV23 vaccine was subsidized. The causal relationship between the pneumococcal vaccination rate and the mortality rate of pneumococcal disease was unclear. Further investigation is deemed necessary.
- Open Access
- 26 June 2022
- Published by Wiley in Respirology Case Reports
- Vol. 10 (7) , e0998
An endobronchial hamartoma observed using narrow band imaging under saline injection: A case report
A light blue line (LBL) was observed along the edge of a lesion using narrow band imaging under saline injection during bronchoscopy in an 82‐year‐old patient with a lobulated mass on the left B4. The histopathological diagnosis was hamartoma with ciliated bronchial epithelium, and we speculated that LBL appeared around the ciliated bronchial epithelium.
- 26 June 2022
- Published by Wiley in Respirology Case Reports
- Vol. 10 (7) , e0998
Open AccessAn endobronchial hamartoma observed using narrow band imaging under saline injection: A case report
A light blue line (LBL) was observed along the edge of a lesion using narrow band imaging under saline injection during bronchoscopy in an 82‐year‐old patient with a lobulated mass on the left B4. The histopathological diagnosis was hamartoma with ciliated bronchial epithelium, and we speculated that LBL appeared around the ciliated bronchial epithelium.
- Open Access
- 30 March 2022
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 15 (1) , 356-361
Acute Exacerbation of Tracheal Obstruction and Severe Respiratory Failure after a Single Dose of 2-Gy Irradiation for Squamous Cell Lung Carcinoma: A Case Report
The patient, a 62-year-old woman, complained chiefly of cough. We planned chemoradiotherapy for squamous nonsmall cell lung cancer. A single dose of 2-Gy irradiation and no anticancer agent administration exacerbated the airway stenosis with severe respiratory failure. Urgent tracheal intubation was performed, and a tracheal stent was implanted under extracorporeal membrane oxygenation (ECMO). Because her performance status (PS) worsened from 1 to 2, we administered radiotherapy. The tumor size decreased. There was no recurrence for the next 3 months, and her PS improved to 1. Emergency tracheal intubation and tracheal stent placement under ECMO can be effective for exacerbated airway obstruction after radiotherapy.
- 30 March 2022
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 15 (1) , 356-361
Open AccessAcute Exacerbation of Tracheal Obstruction and Severe Respiratory Failure after a Single Dose of 2-Gy Irradiation for Squamous Cell Lung Carcinoma: A Case Report
The patient, a 62-year-old woman, complained chiefly of cough. We planned chemoradiotherapy for squamous nonsmall cell lung cancer. A single dose of 2-Gy irradiation and no anticancer agent administration exacerbated the airway stenosis with severe respiratory failure. Urgent tracheal intubation was performed, and a tracheal stent was implanted under extracorporeal membrane oxygenation (ECMO). Because her performance status (PS) worsened from 1 to 2, we administered radiotherapy. The tumor size decreased. There was no recurrence for the next 3 months, and her PS improved to 1. Emergency tracheal intubation and tracheal stent placement under ECMO can be effective for exacerbated airway obstruction after radiotherapy.
- Open Access
- 1 March 2022
- Published by Elsevier in Respiratory Investigation
- Vol. 60 (2) , 215-220
Results of 10-year mobile low-dose computed tomography screenings for lung cancer in Shimane, Japan
- 1 March 2022
- Published by Elsevier in Respiratory Investigation
- Vol. 60 (2) , 215-220
Open AccessResults of 10-year mobile low-dose computed tomography screenings for lung cancer in Shimane, Japan
- Open Access
- 22 February 2022
- Published by Wiley in Respirology Case Reports
- Vol. 10 (3) , e0918
Nontuberculous Mycobacterium‐associated immune reconstitution inflammatory syndrome in a non‐HIV immunosuppressed patient
A 69‐year‐old woman with rheumatoid arthritis, using immunosuppressants, including etanercept—a tumour necrosis factor (TNF)‐α antagonist—was referred to our hospital with fever and fatigue. Chest computed tomography revealed cavities in the left upper lobe. As Mycobacterium intracellulare infection was diagnosed, all immunosuppressants were discontinued, and treatment with anti‐nontuberculous Mycobacterium drugs was initiated. However, her condition worsened paradoxically. We diagnosed immune reconstitution inflammatory syndrome (IRIS) resulting from the discontinuation of the TNF‐α antagonist. Her condition improved with prednisolone treatment. IRIS is generally observed during HIV treatment, but a good understanding of immunosuppressant‐related non‐HIV IRIS is needed.
- 22 February 2022
- Published by Wiley in Respirology Case Reports
- Vol. 10 (3) , e0918
Open AccessNontuberculous Mycobacterium‐associated immune reconstitution inflammatory syndrome in a non‐HIV immunosuppressed patient
A 69‐year‐old woman with rheumatoid arthritis, using immunosuppressants, including etanercept—a tumour necrosis factor (TNF)‐α antagonist—was referred to our hospital with fever and fatigue. Chest computed tomography revealed cavities in the left upper lobe. As Mycobacterium intracellulare infection was diagnosed, all immunosuppressants were discontinued, and treatment with anti‐nontuberculous Mycobacterium drugs was initiated. However, her condition worsened paradoxically. We diagnosed immune reconstitution inflammatory syndrome (IRIS) resulting from the discontinuation of the TNF‐α antagonist. Her condition improved with prednisolone treatment. IRIS is generally observed during HIV treatment, but a good understanding of immunosuppressant‐related non‐HIV IRIS is needed.
- Open Access
- 10 May 2021
- Published by Wiley in Respirology Case Reports
- Vol. 9 (6) , e00766
Use of saline to evaluate a cavity due to Mycobacterium kansasii infection during ultrathin bronchoscopy and endobronchial ultrasonography
A 28‐year‐old man had a cavitary lesion in the upper right lobe with a tree‐in‐bud appearance on chest computed tomography (CT). Diagnostic bronchoscopy was performed. An ultrathin bronchoscope in the right B2aiiβxyy reached the cavity. We filled the cavity with saline under direct bronchoscopic visualization. We suspected a blood vessel was present in the cavity wall based on narrow‐band imaging. Bronchial lavage of the cavity was performed. Next, endobronchial ultrasonography (EBUS) using a guide sheath was performed with a thin bronchoscope. EBUS showed a pulsating blood vessel in the cavity wall. Bronchial lavage collected with ultrathin and thin bronchoscopy revealed Mycobacterium kansasii. Observation of vessels in the wall of a cavitary lesion with ultrathin bronchoscopy and EBUS may be useful for avoiding severe bleeding associated with biopsy of a cavitary lesion.
- 10 May 2021
- Published by Wiley in Respirology Case Reports
- Vol. 9 (6) , e00766
Open AccessUse of saline to evaluate a cavity due to Mycobacterium kansasii infection during ultrathin bronchoscopy and endobronchial ultrasonography
A 28‐year‐old man had a cavitary lesion in the upper right lobe with a tree‐in‐bud appearance on chest computed tomography (CT). Diagnostic bronchoscopy was performed. An ultrathin bronchoscope in the right B2aiiβxyy reached the cavity. We filled the cavity with saline under direct bronchoscopic visualization. We suspected a blood vessel was present in the cavity wall based on narrow‐band imaging. Bronchial lavage of the cavity was performed. Next, endobronchial ultrasonography (EBUS) using a guide sheath was performed with a thin bronchoscope. EBUS showed a pulsating blood vessel in the cavity wall. Bronchial lavage collected with ultrathin and thin bronchoscopy revealed Mycobacterium kansasii. Observation of vessels in the wall of a cavitary lesion with ultrathin bronchoscopy and EBUS may be useful for avoiding severe bleeding associated with biopsy of a cavitary lesion.